Drug Utilization Study of Antiplatelet in Thrombotic Stroke Patients: Studi Penggunaan Antiplatelet Pada Pasien Stroke Trombotik

samirah samirah (Departemen Farmasi Praktis, Universitas Airlangga)
Rafifah Fadhilah (Sarjana Farmasi, Fakultas Farmasi, Universitas Airlangga)
Rifdah Atikah Safitri (Magister Farmasi Klinis, Fakultas Farmasi, Universitas Airlangga)
Abdulloh Machin (Departemen Neurologi, Rumah Sakit Universitas Airlangga)
Suharjono (Airlangga University)
Nafa Rosyida Zanuba (Airlangga University)

Journal Pharmasci (Journal of Pharmacy and Science)
Vol. 10 No. 2 (2025): Journal Pharmasci (Journal of Pharmacy and Science)

Stroke is the mayor cause of death and disability in Indonesia, with the thrombotic stroke being is the leading cause. Thrombotic stroke occurs due to the formation of a thrombus in the brain’s blood vessels, necessitating antiplatelet therapy to prevent recurrent stroke and other cardiovascular diseases. This study aim to identify pattern of antiplatelet therapy, adverse drug reaction, as well as drug-drug interaction related to antiplatelet. A total of 50 adult thrombotic stroke inpatient was observed in this observational-retrospective study. The most frequent antiplatelet used were acetosal (40%), clopidogrel (28%), followed by acetosal clopidogrel combination (28%), and acetosal-cilostazol combination (4%). In this study, 60% of ADR was identified, of which 16% was nausea and vomiting and 44% was dyspepsia. Five potential drug-drug interaction were identified, including acetosal-ACE inhibitor (6%), acetosal-NSAID (24%), Clopidogel-PPI (10%), and Clopidogrel-Statin (48%).